Table 2 Expression of CK19, HBME-1, Galectin-3, CD56 in benign and malignant tumors
Markers | Expression | Tumor | |||
|---|---|---|---|---|---|
Benign | Malignant | ||||
N | % | N | % | ||
CK 19 | + | 23 | 29.1 % | 92 | 75.4 % |
- | 56 | 70.9 % | 30 | 24.6 % | |
HBME 1 | + | 12 | 15.2 % | 87 | 71.3 % |
- | 67 | 84.8 % | 35 | 28.7 % | |
Galectin 3 | + | 28 | 35.4 % | 108 | 88.5 % |
- | 51 | 64.6 % | 14 | 11.5 % | |
CD 56 | + | 6 | 7.6 % | 71 | 58.2 % |
- | 73 | 92.4 % | 51 | 41.8 % | |